Biologic Therapy in Rheumatoid Arthritis / 한양의대학술지
Hanyang Medical Reviews
; : 80-88, 2005.
Article
in Ko
| WPRIM
| ID: wpr-42015
Responsible library:
WPRO
ABSTRACT
Rheumatoid arthritis (RA) is a common autoimmune disease of unknown etiology characterized by symmetric and erosive synovitis. The course of RA is usually chronic and progressive, so it can result destructive joint damages. Nonsteroidal anti-inflammatory drugs, disease modifying anti-rheumatic drugs (DM ARDs) and low-dose corticosteroid have been used for the treatments of RA. The importance of early usage of DMARDs are stressed recently, however, the effects of DMARDs on long-term prognosis is not convincing. Since 1998, several biologic agents were developed for RA and showed promising results. These agents include TNF-alpha blockers such as etanercept, infliximab, adalimumab, and IL-1 receptor antagonist such as anakinra. Clinical studies for rituximab, anti-IL-6 receptor monoclonal antibody, and CTLA4-Ig are underway. The biologic agents show rapid improvement in clinical and laboratory parameters and may prevent the erosions on Xray, but because of costs and unknown long-term side effects, we should be more careful for using these drugs.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Arthritis, Rheumatoid
/
Prognosis
/
Autoimmune Diseases
/
Synovitis
/
Biological Therapy
/
Biological Factors
/
Interleukin-1
/
Tumor Necrosis Factor-alpha
/
Antirheumatic Agents
/
Interleukin 1 Receptor Antagonist Protein
Type of study:
Prognostic_studies
Language:
Ko
Journal:
Hanyang Medical Reviews
Year:
2005
Type:
Article